Chile - hiszpański - ISPC (Instituto de Salud Pública de Chile)

abbvie productos farmacÉuticos ltda. - adalimumab - sin formulas

Chile - hiszpański - ISPC (Instituto de Salud Pública de Chile)

abbvie productos farmacÉuticos ltda. - adalimumab - sin formulas

Kuba - hiszpański - CECMED (Autoridad Reguladora de Medicamentos, Equipos y Dispositivos Médicos)

hetero biopharma limited, bloque iii-a (planta baja) y bloque iii-a (primer piso) - adalimumab - solución para inyección sc - 40 mg/0.8 ml

Unia Europejska - hiszpański - EMA (European Medicines Agency)

alexion europe sas - ravulizumab - hemoglobinuria, paroxística - inmunosupresores selectivos - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Peru - hiszpański - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

adalimumab - solución inyectable - 20mg/0.4ml

Peru - hiszpański - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

adalimumab - solución inyectable - 40mg/0.8ml

Ekwador - hiszpański - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

amgen europe b.v. paises bajos - adalimumab 50 mg/ml cada jeringa prellenada (pfs) de 20 mg/0,4 ml contiene: adalimumab????????. 20 mg cada jeringa prellenada (pfs) o autoinyector prellenado de 40 mg/0,8 ml contiene: adalimumab???????? 40 mg - soluciÓn inyectable - cada jeringa prellenada (pfs) de 20 mg/0,4 ml contiene: adalimumab????????. 20 mg cada jeringa prellenada (pfs) o autoinyector prellenado de 40 mg/0,8 ml contiene: adalimumab???????? 40 mg

Ekwador - hiszpański - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

abbvie deutschland gmbh & co. kg [de] germany - adalimumab 40 mg - solucion inyectable - cada 0,4 ml de solución contiene: adalimumab 40 mg

Ekwador - hiszpański - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

biosimilar collaborations ireland limited [ie] ireland - adalimumab 40 mg/0.8 ml - solucion para inyeccion - cada jeringa precargada (0.8 ml) / cada pluma precargada (0.8 ml), contiene: adalimumab 40,00 mg

Ekwador - hiszpański - Agencia Nacional de Regulación, Control y Vigilancia Sanitaria

ifa/pt: cadila healthcare ltd india - adalimumab 40mg/0.8ml - solucion - cada jeringa prellenada contiene una dosis: adalimumab 40mg/0.8ml